Fineline Cube

Follow:
14496 Articles
China's CDE Slates Highlightll's Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis
CompanyDrug

China’s CDE Slates Highlightll’s Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs
CompanyDeals

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs
CompanyDeals

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection
CompanyDeals

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION
CompanyDrug

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency
CompanyDeals

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC
CompanyDrug

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform
CompanyDeals

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo
Company

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers
CompanyDrug

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers